Ligand id: 9093

Name: satralizumab

Compound class Antibody
International Nonproprietary Names
INN number INN
10065 satralizumab
SA-237 | SA237 | sapelizumab (perviously known as)
Satralizumab (previously referred to using the replaced INN sapelizumab) is an investigational humanized monoclonal antibody targeting the IL-6 receptor, with immunomodulatory potential. This antibody is an improved version of tocilizumab, with enhanced antigen-neutralizing ability and pharmacokinetics suitable for less frequent administration [1].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide BLAST searches reveal identical matches between the heavy and light chain sequences as annotated in IMGT and SEQ IDs 26 and 29 respectively claimed in patent US8562991 [1]. This matches satralizumab to the Fv4-M73 construct in the patent.
Database Links
Specialist databases
IMGT/mAb-DB 586
Other databases
GtoPdb PubChem SID 315661178
Search PubMed clinical trials satralizumab
Search PubMed titles satralizumab
Search PubMed titles/abstracts satralizumab